Groupe Berkem Société anonyme (ALKEM.PA)
| Previous close | 2.2300 |
| Open | 2.2100 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 2.1800 - 2.2400 |
| 52-week range | 1.1800 - 6.1000 |
| Volume | |
| Avg. volume | 14,317 |
| Market cap | 38.613M |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | 109.00 |
| EPS (TTM) | 0.0200 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 04 Jul 2022 |
| 1y target est | 5.20 |
Business WireGroupe Berkem Unveils BiombalanceTM and Pineol® Premium, two Active Ingredients From Its New Nutraceutical Range
BLANQUEFORT, France, May 13, 2024--Regulatory News: Groupe Berkem (Paris:ALKEM), a leading player in bio-based chemistry (ISIN code: FR00140069V2 – Ticker: ALKEM), unveils today Pineol® Premium and BiombalanceTM, from its new range of premium ingredients for the Nutraceutical market.
Business WireGroupe Berkem: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
BLANQUEFORT, France, May 03, 2024--Regulatory News: Groupe Berkem (Paris:ALKEM):
Business WireGroupe Berkem Announces Its Full-Year 2023 Financial Results and Its Revenue for the First Quarter of 2024
BLANQUEFORT, France, April 30, 2024--Regulatory News: Groupe Berkem, a leading player in bio-based chemistry (ISIN code: FR00140069V2 – Ticker: ALKEM), announces its full-year financial results for the year ended December 31, 2023, as approved by its Board of Directors on April 26, 2024. The audit procedures on the full-year accounts have been conducted and the auditors' report is being issued. The Company also reports on its 2024 first-quarter revenue.
